Aromasin 25mg

Dragon Pharma Aromasin — Exemestane 25mg Suicidal Aromatase Inhibitor

Dragon Pharma Aromasin delivers 25 mg of Exemestane per tablet. This steroidal aromatase inhibitor employs a unique irreversible binding mechanism that permanently deactivates the estrogen-converting enzyme.

Unlike reversible competitors, this suicidal AI eliminates the risk of estrogen rebound upon cessation. It is engineered for athletes requiring aggressive estrogen suppression during highly aromatizing anabolic protocols.

Overview

Exemestane is a steroidal compound structurally derived from androstenedione. It functions as a mechanism-based irreversible inhibitor, forming a covalent bond with the aromatase enzyme and permanently inactivating it.

The body must synthesize entirely new aromatase enzymes to restore estrogen production. This provides a smoother hormonal transition and eliminates the rebound spike commonly experienced with non-steroidal reversible inhibitors.

For athletes using strongly aromatizing testosterone derivatives or oral bulking agents, this agent delivers comprehensive protection against gynecomastia, subcutaneous edema, and estrogen-mediated hypertension.

Dragon Pharma subjects every batch to independent laboratory analysis. Recent verification confirmed 24.21 mg per tablet, ensuring precise dosing accuracy and predictable pharmacological outcomes.

Benefits

• Irreversible Enzyme Inactivation: Forms a permanent covalent bond with aromatase, destroying the enzyme rather than merely blocking it. This prevents estrogen rebound after discontinuation.
• Gynecomastia Protection: Drastically reduces circulating estradiol, preventing nipple sensitivity and mammary tissue proliferation behind the areola.
• Subcutaneous Water Elimination: Sheds extracellular fluid driven by estrogen, producing a harder, more defined physique with enhanced vascular detail.
• Smoother Transition Off-Cycle: The suicidal mechanism means no sudden estrogen surge when stopping the compound. The body gradually restores aromatase activity at its own pace.
• Favorable Lipid Profile: Many users report a less severe impact on HDL cholesterol compared to non-steroidal alternatives, particularly at moderate doses.

Main Features

• Precisely dosed 25 mg oral tablets for easy splitting and titration
• Steroidal mechanism-based irreversible aromatase inhibitor
• Covalent binding permanently deactivates the estrogen-converting enzyme
• Zero estrogen rebound risk upon cessation
• Compatible with on-cycle support and select PCT protocols
• Independent laboratory verification of tablet concentration

Ingredients

Each tablet contains 25 mg of Exemestane as the active pharmaceutical ingredient.

Inactive excipients include mannitol, crospovidone, magnesium stearate, and pharmaceutical-grade binders. These ensure tablet hardness, stability, and uniform dissolution characteristics.

All raw materials are validated for chemical identity and purity prior to compression and film-coating.

How to Use

Ingest tablets with a meal containing dietary fats to enhance absorption of this steroidal compound. Consistency in timing supports stable plasma concentrations.

Begin administration 1–2 weeks after initiating aromatizing compounds, or at the first indication of estrogenic symptoms. Continue throughout the entire anabolic protocol.

Store the container in a cool, dry environment between 15–25°C (59–77°F). Protect from moisture and direct light. Keep the desiccant pouch intact.

Dosage

Mild to moderate cycles utilizing 300–500 mg weekly of testosterone typically respond to 12.5 mg every other day. This equals half a tablet and serves as an excellent starting point.

Moderate to heavy cycles with strongly aromatizing stacks may require 12.5 mg daily. Assess symptoms and laboratory values before escalating beyond this threshold.

Extremely estrogenic protocols involving high-dose testosterone or multiple aromatizing compounds may necessitate 25 mg daily. This represents the upper limit and should be approached with caution.

Always initiate at the lowest effective dose. Recovering from crashed estrogen is more challenging than incrementally increasing suppression.

Side Effects

Estrogen depletion is the primary dose-dependent adverse effect. Manifestations include aching joints, decreased libido, mood disturbances, and persistent fatigue.

These symptoms resolve through dose reduction or temporary discontinuation. Allowing estradiol to rebound slightly typically restores comfort within several days.

Lipid profiles may shift unfavorably, though generally less severely than with non-steroidal alternatives. Regular lipid panels and cardiovascular support remain advisable.

As a steroidal compound derived from androstenedione, there is a theoretical potential for mild androgenic activity at very high doses. This is rarely observed at standard bodybuilding dosages.

Safety Information

This product is intended exclusively for research purposes and use by qualified adults under appropriate supervision. It is not suitable for minors, pregnant or nursing women, or individuals with pre-existing hepatic or lipid disorders.

Regular blood work monitoring estradiol, liver enzymes, and lipid panels is essential throughout the cycle. Adjust dosing based on objective laboratory values rather than symptoms alone.

Maintain a heart-healthy diet rich in omega-3 fatty acids and low in saturated fats. Regular cardiovascular exercise supports lipid management and vascular health.

Discontinue immediately and seek medical evaluation if severe joint pain, depression, or persistent fatigue develop.

Aromasin can be incorporated into Post-Cycle Therapy at 12.5 mg every other day for the first two weeks alongside SERMs. The lack of rebound makes this transition smoother than with reversible inhibitors.